Exosomes Market
Exosomes Market
The market for Exosomes was estimated at $198.14 million in 2024; it is anticipated to increase to $1.04 billion by 2030, with projections indicating growth to around $4.13 billion by 2035.
Global Exosomes Market Outlook
Revenue, 2024 (US$M)
$198M
Forecast, 2034 (US$B)
$3.13B
CAGR, 2024 - 2034
31.8%
Market Key Insights
- The Exosomes market is projected to grow from $198.1 million in 2024 to $3.13 billion in 2034. This represents a CAGR of 31.8%, reflecting rising demand across Therapeutic, Diagnostic and Regenerative Medicine.
- Thermo Fisher Scientific Inc., System Biosciences LLC, Norgen Biotek Corp. are among the leading players in this market, shaping its competitive landscape.
- U.S. and China are the top markets within the Exosomes market and are expected to observe the growth CAGR of 30.5% to 44.5% between 2024 and 2030.
- Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 23.9% to 33.1%.
- Transition like Exosomes in Diagnostics is expected to add $402.7 million to the Exosomes market growth by 2030
- The Exosomes market is set to add $2.9 billion between 2024 and 2034, with manufacturer targeting Regenerative Medicine & Drug Delivery Applications projected to gain a larger market share.
- With Rising prevalence of cancer, and Advancements in technology, Exosomes market to expand 1482% between 2024 and 2034.
Opportunities in the Exosomes
The concept of healthcare is on the rise with a focus on customizing treatment based on each patients unique genetic characteristics. A key player, in this area could be exosomes that transport protein details from their original cells.
Growth Opportunities in North America and Asia-Pacific
North America Outlook
Asia-Pacific Outlook
Market Dynamics and Supply Chain
Driver: Rising Prevalence of Cancer, and Increasing Investment in Research and Development
Restraint: High Cost of Exosome Isolation and Analysis
Opportunity: Advancements in Regenerative Medicine and Strategic Collaborations in Cancer Research
Challenge: Regulatory Challenges
Supply Chain Landscape
Research & Development
Thermo Fisher Scientific
Bio-Techne Corporation
Production & Isolation
HansaBioMed Life Sciences
System Biosciences
Packaging & Distribution
Lonza Group
Qiagen
End Users
Diagnostic Laboratories
Pharmaceutical and Biotechnology Companies
Hospitals and Clinics
Research & Development
Thermo Fisher Scientific
Bio-Techne Corporation
Production & Isolation
HansaBioMed Life Sciences
System Biosciences
Packaging & Distribution
Lonza Group
Qiagen
End Users
Diagnostic Laboratories
Pharmaceutical and Biotechnology Companies
Hospitals and Clinics